3VG.F Stock Analysis
3V
Uncovered
Theranexus SA is uncovered by Eyestock quantitative analysis.
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 19 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.